Mei Zeng1, Mitchell Szymczak2, Malini Ahuja2, Changyu Zheng2, Hongen Yin2, William Swaim2, John A Chiorini2, Robert J Bridges3, Shmuel Muallem4. 1. Molecular Physiology and Therapeutics Branch, National Institutes of Health, National Institute of Dental and Craniofacial Research, Bethesda, Maryland; North Sichuan Medical College, Sichuan, China. 2. Molecular Physiology and Therapeutics Branch, National Institutes of Health, National Institute of Dental and Craniofacial Research, Bethesda, Maryland. 3. Department of Physiology and Biophysics, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois. 4. Molecular Physiology and Therapeutics Branch, National Institutes of Health, National Institute of Dental and Craniofacial Research, Bethesda, Maryland. Electronic address: shmuel.muallem@nih.gov.
Abstract
BACKGROUND & AIMS: Sjögren's syndrome and autoimmune pancreatitis are disorders with decreased function of salivary, lacrimal glands, and the exocrine pancreas. Nonobese diabetic/ShiLTJ mice and mice transduced with the cytokine BMP6 develop Sjögren's syndrome and chronic pancreatitis and MRL/Mp mice are models of autoimmune pancreatitis. Cystic fibrosis transmembrane conductance regulator (CFTR) is a ductal Cl- channel essential for ductal fluid and HCO3- secretion. We used these models to ask the following questions: is CFTR expression altered in these diseases, does correction of CFTR correct gland function, and most notably, does correcting ductal function correct acinar function? METHODS: We treated the mice models with the CFTR corrector C18 and the potentiator VX770. Glandular, ductal, and acinar cells damage, infiltration, immune cells and function were measured in vivo and in isolated duct/acini. RESULTS: In the disease models, CFTR expression is markedly reduced. The salivary glands and pancreas are inflamed with increased fibrosis and tissue damage. Treatment with VX770 and, in particular, C18 restored salivation, rescued CFTR expression and localization, and nearly eliminated the inflammation and tissue damage. Transgenic overexpression of CFTR exclusively in the duct had similar effects. Most notably, the markedly reduced acinar cell Ca2+ signaling, Orai1, inositol triphosphate receptors, Aquaporin 5 expression, and fluid secretion were restored by rescuing ductal CFTR. CONCLUSIONS: Our findings reveal that correcting ductal function is sufficient to rescue acinar cell function and suggests that CFTR correctors are strong candidates for the treatment of Sjögren's syndrome and pancreatitis.
BACKGROUND & AIMS: Sjögren's syndrome and autoimmune pancreatitis are disorders with decreased function of salivary, lacrimal glands, and the exocrine pancreas. Nonobese diabetic/ShiLTJ mice and mice transduced with the cytokine BMP6 develop Sjögren's syndrome and chronic pancreatitis and MRL/Mp mice are models of autoimmune pancreatitis. Cystic fibrosis transmembrane conductance regulator (CFTR) is a ductal Cl- channel essential for ductal fluid and HCO3- secretion. We used these models to ask the following questions: is CFTR expression altered in these diseases, does correction of CFTR correct gland function, and most notably, does correcting ductal function correct acinar function? METHODS: We treated the mice models with the CFTR corrector C18 and the potentiator VX770. Glandular, ductal, and acinar cells damage, infiltration, immune cells and function were measured in vivo and in isolated duct/acini. RESULTS: In the disease models, CFTR expression is markedly reduced. The salivary glands and pancreas are inflamed with increased fibrosis and tissue damage. Treatment with VX770 and, in particular, C18 restored salivation, rescued CFTR expression and localization, and nearly eliminated the inflammation and tissue damage. Transgenic overexpression of CFTR exclusively in the duct had similar effects. Most notably, the markedly reduced acinar cell Ca2+ signaling, Orai1, inositol triphosphate receptors, Aquaporin 5 expression, and fluid secretion were restored by rescuing ductal CFTR. CONCLUSIONS: Our findings reveal that correcting ductal function is sufficient to rescue acinar cell function and suggests that CFTR correctors are strong candidates for the treatment of Sjögren's syndrome and pancreatitis.
Authors: Jennifer K King; Rachael L Philips; Anna U Eriksson; Peter J Kim; Ramesh C Halder; Delphine J Lee; Ram Raj Singh Journal: J Immunol Date: 2015-06-12 Impact factor: 5.422
Authors: Michael P Boyle; Scott C Bell; Michael W Konstan; Susanna A McColley; Steven M Rowe; Ernst Rietschel; Xiaohong Huang; David Waltz; Naimish R Patel; David Rodman Journal: Lancet Respir Med Date: 2014-06-24 Impact factor: 30.700
Authors: Alyssa M Flores; Scott D Casey; Christian M Felix; Puay W Phuan; A S Verkman; Marc H Levin Journal: FASEB J Date: 2016-02-03 Impact factor: 5.191
Authors: Andrea E Potash; Tanner J Wallen; Philip H Karp; Sarah Ernst; Thomas O Moninger; Nicholas D Gansemer; David A Stoltz; Joseph Zabner; Eugene H Chang Journal: Mol Ther Date: 2013-03-19 Impact factor: 11.454
Authors: Leyla Y Teos; Yu Zhang; Ana P Cotrim; William Swaim; Jon H Won; Julian Ambrus; Long Shen; Lolita Bebris; Margaret Grisius; Shyh-Ing Jang; David I Yule; Indu S Ambudkar; Ilias Alevizos Journal: Sci Rep Date: 2015-09-14 Impact factor: 4.379
Authors: Claudia D'Agostino; Osama A Elkashty; Clara Chivasso; Jason Perret; Simon D Tran; Christine Delporte Journal: Cells Date: 2020-06-25 Impact factor: 6.600